BioXcel Therapeutics申请Chapter 11破产保护，Teva以5750万美元现金加最高8750万美元里程碑付款作为Stalking Horse竞购方收购其核心资产

----- 0001104659-26-102570.txt -----
0001104659-26-102570.txt : 20260828
0001104659-26-102570.hdr.sgml : 20260828
20260828060029
ACCESSION NUMBER: 0001104659-26-102570
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 11
CONFORMED PERIOD OF REPORT: 20260827
ITEM INFORMATION: Entry into a Material Definitive Agreement
ITEM INFORMATION: Bankruptcy or Receivership
FILED AS OF DATE: 20260828
DATE AS OF CHANGE: 20260828
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: BioXcel Therapeutics, Inc.
CENTRAL INDEX KEY: 0001720893
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
EIN: 821386754
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38410
FILM NUMBER: 261332659
BUSINESS ADDRESS:
STREET 1: 555 LONG WHARF DRIVE
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
BUSINESS PHONE: 203-643-8060
MAIL ADDRESS:
STREET 1: 555 LONG WHARF DRIVE
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
8-K
1
tm2624233d1_8k.htm
FORM 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 27, 2026
BioXcel
Therapeutics, Inc.
(Exact name of registrant as specified in its
charter)
Delaware
001-38410
82-1386754
(State
or other jurisdiction of
incorporation)
(Commission
File Number)
(I.R.S.
Employer
Identification No.)
555
Long Wharf Drive
New
Haven
,
CT
06511
(Address of principal executive offices, including
Zip Code)
(
475
)
238-6837
(Registrant’s telephone number, including
area code
)
N/A
(Former name or former address, if changed
since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
¨
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered
pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
Common
Stock, par value $0.001
BTAI
The
Nasdaq
Capital Market
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 1.01
Entry into a Material Definitive
Agreement.
The information set forth below in Item 1.03
of this Current Report on Form 8-K is incorporated herein by reference.
Item 1.03
Bankruptcy or Receivership.
On August 27, 2026 (the “Petition Date”), BioXcel Therapeutics, Inc. (the “Company”) and its subsidiaries OnkosXcel
Therapeutics, LLC and OnkosXcel Employee Holdings, LLC (together with the Company, the “Debtors”) each filed voluntary petitions
for relief under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (such court, the
“Court” and such cases, the “Cases”). The Debtors have requested that the Cases be jointly administered under
the caption “In re BioXcel Therapeutics, Inc., et al.” The Debtors will continue to operate their businesses as “debtors-in-possession”
under the jurisdiction of the Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Court. To
ensure its ability to continue operating in the ordinary course of business, the Company has filed with the Court motions seeking a variety
of “first-day” relief (collectively, the “First Day Motions”).
In addition, the Company filed, or is expected to shortly file, with
the Court a motion seeking approval of debtor-in-possession financing (“DIP Financing”) to fund post-petition operations and
costs in the ordinary course. The DIP Financing is expected to be provided by affiliates of Oaktree Capital Management, L.P. and the Qatar
Investment Authority, which are the same parties (or affiliates thereof) that provided prepetition financing to the Company under the
Debtors’ existing Credit Agreement and Guaranty, dated as of April 19, 2022 (as amended through August 24, 2026, the “Prepetition
Credit Agreement”), and to consist of (i) new money term loan commitments in an aggregate principal amount of up to $19 million,
available in two draws: an initial draw of up to $9.5 million upon entry of the interim DIP order and an additional draw of up to $9.5
million upon entry of the final DIP order, and (ii) roll-up loans in an aggregate principal amount of up to $58.25 million, resulting
from the conversion of a portion of the prepetition obligations outstanding under the Prepetition Credit Agreement into obligations under
the DIP Financing on a dollar-for-dollar basis.
The Company’s objective in the Cases is
to maximize value for its stakeholders, which may be achieved through the sale of all or substantially all assets to the highest bidder
or bidders. Additional information about the Cases, including access to Court documents, is available online
https://cases.stretto.com/BioXcel
,
a website administered by Stretto, a third-party bankruptcy claims and noticing agent. The information on this website is not incorporated
by reference into, and does not constitute part of, this Current Report on Form 8-K.
In connection with the foregoing, the Company appointed
Samir Saleem as the Chief Restructuring Officer (the “CRO”) of the Company to assist with certain executive management, restructuring,
lender relationship management, accounting management, operations support, and communication. The CRO will report to a Strategic Process
Committee of the Board that was appointed pursuant to the Prepetition Credit Agreement in order to evaluate, negotiate, oversee, coordinate
and implement any sale, restructuring or other material transactions, including the Case.
Stalking Horse Asset Purchase Agreement
On August 27, 2026, the Debtors entered into an
asset purchase agreement (the “Stalking Horse APA”) by and among the Debtors, Teva Pharmaceuticals International GmbH, a Swiss
limited liability company (“Teva”), and Teva Pharmaceutical Industries Limited, a company incorporated under the laws of Israel
(solely as guarantor of Teva’s milestone obligations for purposes of Section 9.16 of the Stalking Horse APA).
Pursuant to the Stalking Horse APA, the Company
has agreed to sell, and Teva has agreed to acquire, subject to the terms and conditions contained therein, substantially all of the Debtors’
assets (collectively, the “Assets”), and to assume certain specified liabilities of the Debtors (collectively, the “Liabilities”
and such acquisition of the Assets and assumption of the Liabilities, the “Transaction”) for consideration of upfront cash
in the amount of $57.5 million, assumption of the Liabilities, plus up to $67.5 million of contingent “Development Milestone Payments”
tied to the outcome and timing of the pending sNDA for IGALMI® at-home use (the “sNDA”). Depending on the timing of approval
of the pending sNDA, the Debtors may also be entitled to up to $20 million in Commercial Milestone payments, depending on net sales reaching
certain sales thresholds post-closing. Under the Stalking Horse APA, Teva has agreed to serve as the “stalking horse” bidder
in respect of the Assets, and the Transaction remains subject to higher or otherwise better bids in connection with the auction process
to be conducted by the Debtors in the Cases.
The Transaction, and the designation of Teva as
the stalking horse bidder, is subject to the approval of the Court. As the proposed stalking horse bidder, Teva’s offer to purchase
the Assets and assume the Liabilities, as set forth in the Stalking Horse APA, would serve as the minimum, or floor, bid. On August 27,
2026, the Company filed a motion with the Court seeking authority to sell the Assets to Teva pursuant to Section 363 of the Bankruptcy
Code, subject to higher or otherwise better bids, approval of the proposed bidding procedures, designation of Teva as the stalking horse
bidder for the Assets, certain bid protections for the stalking horse bidder, and a motion requesting a hearing on approval of the bidding
procedures (the “Sale Motion”).
The Stalking Horse APA contains customary representations,
warranties and covenants of the parties for a transaction involving the acquisition of assets from debtors in bankruptcy, and the completion
of the Transaction is subject to a number of customary conditions, which, among others, include the entry of an order of the Court authorizing
and approving the Transaction, the performance by each party of its obligations under the Stalking Horse APA and the material accuracy
of each party’s representations.
The Stalking Horse APA contains customary termination
provisions, including rights exercisable by either party, by the Company alone or by Teva alone upon the occurrence of specified events,
including failure to satisfy specified case milestones, material breach by the other party, failure to consummate the Transaction by October
30, 2026, and the occurrence of certain Court or case-related events adverse to Teva.
The foregoing summary of the Stalking Horse APA
is not complete and is qualified in its entirety by reference to the full text of the Stalking Horse APA, a copy of which will be filed
as an exhibit to an amendment to this Current Report on Form 8-K.
The representations, warranties and covenants set
forth in the Stalking Horse APA have been made only for purposes of the Stalking Horse APA and solely for the benefit of the parties thereto,
and may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures made for
the purposes of allocating contractual risk between the parties to the Stalking Horse APA instead of establishing these matters as facts.
In addition, information regarding the subject matter of the representations and warranties made in the Stalking Horse APA may change
after the date of the Stalking Horse APA and do not purport to be accurate as of the date of this Current Report on Form 8-K. Accordingly,
investors should not rely upon the representations and warranties in the Stalking Horse APA as statements of factual information.
Cautionary Note Regarding Forward-Looking Statements
This Current Report on Form 8-K may contain
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,”
“believes,” “expects,” “intends,” “potential,” “projects,” “target,”
“will,” “would” and “future” or similar expressions are intended to identify forward-looking statements.
Forward-looking statements in this report include statements concerning, among other things, the Cases, the Company’s ability to
complete the Transaction and its ability to continue operating in the ordinary course while the Cases are pending, and other statements
that are not historical fact. These statements are based upon the current expectations and beliefs of management and are subject to certain
risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
These risks and uncertainties include, but are not limited to: (i) risks related to the consummation of the Transaction; (ii) potential
adverse effects of the Cases on the Company’s liquidity and results of operations; (iii) the Company’s ability to obtain
timely approval by the Court of the motions filed in the Cases; (iv) objections to the Transaction, the bidding procedures, or other
pleadings filed that could protract the Cases; (v) employee attrition and the Company’s ability to retain senior management and
other key personnel due to the distractions and uncertainties; (vi) the Company’s ability to comply with the restrictions imposed
by the terms and conditions of the Company’s financing arrangements, including the DIP Facility; (vii) the Company’s ability
to maintain relationships with suppliers, vendors, partners, employees and other third parties and regulatory authorities as a result
of the Cases; (viii) the effects of the Cases on the Company and on the interests of various constituents, including holders of the Company’s
common stock; (ix) the Court’s rulings in the Cases, including the approvals of the terms and conditions of the Transaction, and
the outcome of the Cases generally; (x) the length of time that the Company will operate under Chapter 11 protection and the continued
availability of operating capital during the pendency of the Cases; (xi) risks associated with third party motions in the Cases, which
may interfere with the Company’s ability to consummate the Transaction or an alternative transaction; (xii) increased administrative
and legal costs related to the Chapter 11 process; (xiii) exposure to potential litigation, including related to the Transaction, and
inherent risks involved in a bankruptcy process; (xiv) the occurrence of any event, change or other circumstances that could give rise
to the right of the Company or Teva to terminate the Stalking Horse APA; (xv) the possibility that the anticipated benefits of the Transaction
are not realized when expected or at all, including that the Transaction contemplates contingent payments upon the occurrence of milestone
events that may never be achieved; (xvi) the possibility that the Transaction may be more expensive to complete than anticipated; (xvii)
diversion of management’s attention from ongoing business operations and opportunities; (xviii) potential adverse reactions or
changes to business or employee relationships, including those resulting from the bankruptcy proceedings of the Company or announcement
or completion of the Transaction; (xix) the risk that the Company will not realize the anticipated benefits of its reduction in force;
and other risks and uncertainties, including those described in the section entitled “Risk Factors” in the Company’s
most recent annual or quarterly report filed with the Securities and Exchange Commission and in other filings the Company makes with
the Securities and Exchange Commission from time to time. The forward-looking statements herein do not constitute guarantees of future
performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements
speak only as of the date hereof. The Company undertakes no obligation to update the information contained in this Current Report on
Form 8-K to reflect new events or circumstances, except as required by law.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 28, 2026
BIOXCEL THERAPEUTICS, INC.
/s/ Richard Steinhart
By:
Richard Steinhart
Title:
Chief Financial Officer
EX-101.SCH
2
btai-20260827.xsd
XBRL TAXONOMY EXTENSION SCHEMA
00000001 - Document - Cover
link:presentationLink
link:calculationLink
link:definitionLink
EX-101.LAB
3
btai-20260827_lab.xml
XBRL TAXONOMY EXTENSION LABEL LINKBASE
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
EX-101.PRE
4
btai-20260827_pre.xml
XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
XML
6
R1.htm
IDEA: XBRL DOCUMENT
Cover
Aug. 27, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Aug. 27, 2026
Entity File Number
001-38410
Entity Registrant Name
BioXcel
Therapeutics, Inc.
Entity Central Index Key
0001720893
Entity Tax Identification Number
82-1386754
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
555
Long Wharf Drive
Entity Address, City or Town
New
Haven
Entity Address, State or Province
CT
Entity Address, Postal Zip Code
06511
City Area Code
475
Local Phone Number
238-6837
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common
Stock, par value $0.001
Trading Symbol
BTAI
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
XML
7
report.css
IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
.report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
.report table.authRefData a {
display: block;
font-weight: bold;
}
.report table.authRefData p {
margin-top: 0px;
}
.report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
.report table.authRefData .hide a:hover {
background-color: #2F4497;
}
.report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
.report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
.pl a, .pl a:visited {
color: black;
text-decoration: none;
}
/* table */
.report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}
.report hr {
border: 1px solid #acf;
}
/* Top labels */
.report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}
.report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
.report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
.report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}
.report td.pl div.a {
width: 200px;
}
.report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
.report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
.report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
.report .re, .report .reu {
background-color: #def;
}
.report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
.report .ro, .report .rou {
background-color: white;
}
.report .rou td {
border-bottom: 1px solid black;
}
.report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
.report .fn {
white-space: nowrap;
}
/* styles for numeric types */
.report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
.report .nump {
padding-left: 2em;
}
.report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
.report .text {
text-align: left;
white-space: normal;
}
.report .text .big {
margin-bottom: 1em;
width: 17em;
}
.report .text .more {
display: none;
}
.report .text .note {
font-style: italic;
font-weight: bold;
}
.report .text .small {
width: 10em;
}
.report sup {
font-style: italic;
}
.report .outerFootnotes {
font-size: 1em;
}
XML
8
Show.js
IDEA: XBRL DOCUMENT
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
XML
10
FilingSummary.xml
IDEA: XBRL DOCUMENT
3.26.1
html
1
22
1
false
0
0
false
0
false
false
R1.htm
00000001 - Document - Cover
Sheet
http://bioxceltherapeutics.com/role/Cover
Cover
Cover
1
false
false
All Reports
Book
All Reports
btai-20260827.xsd
btai-20260827_lab.xml
btai-20260827_pre.xml
tm2624233d1_8k.htm
http://xbrl.sec.gov/dei/2025
true
false
JSON
12
MetaLinks.json
IDEA: XBRL DOCUMENT
{
"version": "2.2",
"instance": {
"tm2624233d1_8k.htm": {
"nsprefix": "BTAI",
"nsuri": "http://bioxceltherapeutics.com/20260827",
"dts": {
"schema": {
"local": [
"btai-20260827.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
"https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
"https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
"https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
"https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
"https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
"https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
"https://xbrl.sec.gov/country/2025/country-2025.xsd",
"https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
"https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
]
},
"labelLink": {
"local": [
"btai-20260827_lab.xml"
]
},
"presentationLink": {
"local": [
"btai-20260827_pre.xml"
]
},
"inline": {
"local": [
"tm2624233d1_8k.htm"
]
}
},
"keyStandard": 22,
"keyCustom": 0,
"axisStandard": 0,
"axisCustom": 0,
"memberStandard": 0,
"memberCustom": 0,
"hidden": {
"total": 2,
"http://xbrl.sec.gov/dei/2025": 2
},
"contextCount": 1,
"entityCount": 1,
"segmentCount": 0,
"elementCount": 59,
"unitCount": 0,
"baseTaxonomies": {
"http://xbrl.sec.gov/dei/2025": 22
},
"report": {
"R1": {
"role": "http://bioxceltherapeutics.com/role/Cover",
"longName": "00000001 - Document - Cover",
"shortName": "Cover",
"isDefault": "true",
"groupType": "document",
"subGroupType": "",
"menuCat": "Cover",
"order": "1",
"firstAnchor": {
"contextRef": "AsOf2026-08-27",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"span",
"b",
"p",
"body",
"html"
],
"reportCount": 1,
"baseRef": "tm2624233d1_8k.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "AsOf2026-08-27",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"span",
"b",
"p",
"body",
"html"
],
"reportCount": 1,
"baseRef": "tm2624233d1_8k.htm",
"first": true,
"unique": true
}
}
},
"tag": {
"dei_AmendmentDescription": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "AmendmentDescription",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Amendment Description",
"documentation": "Description of changes contained within amended document."
}
}
},
"auth_ref": []
},
"dei_AmendmentFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "AmendmentFlag",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Amendment Flag",
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
}
}
},
"auth_ref": []
},
"dei_AnnualInformationForm": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "AnnualInformationForm",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Annual Information Form",
"documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
}
}
},
"auth_ref": [
"r14"
]
},
"dei_AuditedAnnualFinancialStatements": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "AuditedAnnualFinancialStatements",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Audited Annual Financial Statements",
"documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
}
}
},
"auth_ref": [
"r14"
]
},
"dei_CityAreaCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "CityAreaCode",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "City Area Code",
"documentation": "Area code of city"
}
}
},
"auth_ref": []
},
"dei_CountryRegion": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "CountryRegion",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Country Region",
"documentation": "Region code of country"
}
}
},
"auth_ref": []
},
"dei_CoverAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "CoverAbstract",
"lang": {
"en-us": {
"role": {
"label": "Cover [Abstract]",
"documentation": "Cover page."
}
}
},
"auth_ref": []
},
"dei_CurrentFiscalYearEndDate": {
"xbrltype": "gMonthDayItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "CurrentFiscalYearEndDate",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Current Fiscal Year End Date",
"documentation": "End date of current fiscal year in the format --MM-DD."
}
}
},
"auth_ref": []
},
"dei_DocumentAccountingStandard": {
"xbrltype": "accountingStandardItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "DocumentAccountingStandard",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Accounting Standard",
"documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
}
}
},
"auth_ref": [
"r13"
]
},
"dei_DocumentAnnualReport": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "DocumentAnnualReport",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Annual Report",
"documentation": "Boolean flag that is true only for a form used as an annual report."
}
}
},
"auth_ref": [
"r11",
"r13",
"r14"
]
},
"dei_DocumentFiscalPeriodFocus": {
"xbrltype": "fiscalPeriodItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "DocumentFiscalPeriodFocus",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Fiscal Period Focus",
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
}
}
},
"auth_ref": []
},
"dei_DocumentFiscalYearFocus": {
"xbrltype": "gYearItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "DocumentFiscalYearFocus",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Fiscal Year Focus",
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
}
}
},
"auth_ref": []
},
"dei_DocumentPeriodEndDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "DocumentPeriodEndDate",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Period End Date",
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
}
}
},
"auth_ref": []
},
"dei_DocumentPeriodStartDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "DocumentPeriodStartDate",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Period Start Date",
"documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
}
}
},
"auth_ref": []
},
"dei_DocumentQuarterlyReport": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "DocumentQuarterlyReport",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Quarterly Report",
"documentation": "Boolean flag that is true only for a form used as an quarterly report."
}
}
},
"auth_ref": [
"r12"
]
},
"dei_DocumentRegistrationStatement": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "DocumentRegistrationStatement",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Registration Statement",
"documentation": "Boolean flag that is true only for a form used as a registration statement."
}
}
},
"auth_ref": [
"r0"
]
},
"dei_DocumentShellCompanyEventDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "DocumentShellCompanyEventDate",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Shell Company Event Date",
"documentation": "Date of event requiring a shell company report."
}
}
},
"auth_ref": [
"r13"
]
},
"dei_DocumentShellCompanyReport": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "DocumentShellCompanyReport",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Shell Company Report",
"documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
}
}
},
"auth_ref": [
"r13"
]
},
"dei_DocumentTransitionReport": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "DocumentTransitionReport",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Transition Report",
"documentation": "Boolean flag that is true only for a form used as a transition report."
}
}
},
"auth_ref": [
"r15"
]
},
"dei_DocumentType": {
"xbrltype": "submissionTypeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "DocumentType",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Document Type",
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
}
}
},
"auth_ref": []
},
"dei_DocumentsIncorporatedByReferenceTextBlock": {
"xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "DocumentsIncorporatedByReferenceTextBlock",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Documents Incorporated by Reference [Text Block]",
"documentation": "Documents incorporated by reference."
}
}
},
"auth_ref": [
"r3"
]
},
"dei_EntityAddressAddressLine1": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityAddressAddressLine1",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Line One",
"documentation": "Address Line 1 such as Attn, Building Name, Street Name"
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine2": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityAddressAddressLine2",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Line Two",
"documentation": "Address Line 2 such as Street or Suite number"
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine3": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityAddressAddressLine3",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Line Three",
"documentation": "Address Line 3 such as an Office Park"
}
}
},
"auth_ref": []
},
"dei_EntityAddressCityOrTown": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityAddressCityOrTown",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, City or Town",
"documentation": "Name of the City or Town"
}
}
},
"auth_ref": []
},
"dei_EntityAddressCountry": {
"xbrltype": "countryCodeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityAddressCountry",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Country",
"documentation": "ISO 3166-1 alpha-2 country code."
}
}
},
"auth_ref": []
},
"dei_EntityAddressPostalZipCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityAddressPostalZipCode",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Postal Zip Code",
"documentation": "Code for the postal or zip code"
}
}
},
"auth_ref": []
},
"dei_EntityAddressStateOrProvince": {
"xbrltype": "stateOrProvinceItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityAddressStateOrProvince",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, State or Province",
"documentation": "Name of the state or province."
}
}
},
"auth_ref": []
},
"dei_EntityBankruptcyProceedingsReportingCurrent": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityBankruptcyProceedingsReportingCurrent",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Bankruptcy Proceedings, Reporting Current",
"documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
}
}
},
"auth_ref": [
"r6"
]
},
"dei_EntityCentralIndexKey": {
"xbrltype": "centralIndexKeyItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityCentralIndexKey",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Central Index Key",
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntityCommonStockSharesOutstanding": {
"xbrltype": "sharesItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityCommonStockSharesOutstanding",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Common Stock, Shares Outstanding",
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
}
}
},
"auth_ref": []
},
"dei_EntityCurrentReportingStatus": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityCurrentReportingStatus",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Current Reporting Status",
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
}
}
},
"auth_ref": []
},
"dei_EntityEmergingGrowthCompany": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityEmergingGrowthCompany",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Emerging Growth Company",
"documentation": "Indicate if registrant meets the emerging growth company criteria."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntityExTransitionPeriod": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityExTransitionPeriod",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Elected Not To Use the Extended Transition Period",
"documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
}
}
},
"auth_ref": [
"r19"
]
},
"dei_EntityFileNumber": {
"xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityFileNumber",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity File Number",
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
}
}
},
"auth_ref": []
},
"dei_EntityFilerCategory": {
"xbrltype": "filerCategoryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityFilerCategory",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Filer Category",
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntityIncorporationStateCountryCode": {
"xbrltype": "edgarStateCountryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityIncorporationStateCountryCode",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Incorporation, State or Country Code",
"documentation": "Two-character EDGAR code representing the state or country of incorporation."
}
}
},
"auth_ref": []
},
"dei_EntityInteractiveDataCurrent": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityInteractiveDataCurrent",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Interactive Data Current",
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
}
}
},
"auth_ref": [
"r16"
]
},
"dei_EntityPrimarySicNumber": {
"xbrltype": "sicNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityPrimarySicNumber",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Primary SIC Number",
"documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
}
}
},
"auth_ref": [
"r14"
]
},
"dei_EntityPublicFloat": {
"xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityPublicFloat",
"crdr": "credit",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Public Float",
"documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
}
}
},
"auth_ref": []
},
"dei_EntityRegistrantName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityRegistrantName",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Registrant Name",
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntityShellCompany": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityShellCompany",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Shell Company",
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntitySmallBusiness": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntitySmallBusiness",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Small Business",
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntityTaxIdentificationNumber": {
"xbrltype": "employerIdItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityTaxIdentificationNumber",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Tax Identification Number",
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_EntityVoluntaryFilers": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityVoluntaryFilers",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Voluntary Filers",
"documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
}
}
},
"auth_ref": []
},
"dei_EntityWellKnownSeasonedIssuer": {
"xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityWellKnownSeasonedIssuer",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Well-known Seasoned Issuer",
"documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
}
}
},
"auth_ref": [
"r17"
]
},
"dei_Extension": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "Extension",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Extension",
"documentation": "Extension number for local phone number."
}
}
},
"auth_ref": []
},
"dei_LocalPhoneNumber": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "LocalPhoneNumber",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Local Phone Number",
"documentation": "Local phone number for entity."
}
}
},
"auth_ref": []
},
"dei_NoTradingSymbolFlag": {
"xbrltype": "trueItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "NoTradingSymbolFlag",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "No Trading Symbol Flag",
"documentation": "Boolean flag that is true only for a security having no trading symbol."
}
}
},
"auth_ref": []
},
"dei_OtherReportingStandardItemNumber": {
"xbrltype": "otherReportingStandardItemNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "OtherReportingStandardItemNumber",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Other Reporting Standard Item Number",
"documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
}
}
},
"auth_ref": [
"r13"
]
},
"dei_PreCommencementIssuerTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "PreCommencementIssuerTenderOffer",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Pre-commencement Issuer Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
}
}
},
"auth_ref": [
"r7"
]
},
"dei_PreCommencementTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "PreCommencementTenderOffer",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Pre-commencement Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
}
}
},
"auth_ref": [
"r9"
]
},
"dei_Security12bTitle": {
"xbrltype": "securityTitleItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "Security12bTitle",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Title of 12(b) Security",
"documentation": "Title of a 12(b) registered security."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_Security12gTitle": {
"xbrltype": "securityTitleItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "Security12gTitle",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Title of 12(g) Security",
"documentation": "Title of a 12(g) registered security."
}
}
},
"auth_ref": [
"r5"
]
},
"dei_SecurityExchangeName": {
"xbrltype": "edgarExchangeCodeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "SecurityExchangeName",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Security Exchange Name",
"documentation": "Name of the Exchange on which a security is registered."
}
}
},
"auth_ref": [
"r4"
]
},
"dei_SecurityReportingObligation": {
"xbrltype": "securityReportingObligationItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "SecurityReportingObligation",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Security Reporting Obligation",
"documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
}
}
},
"auth_ref": [
"r10"
]
},
"dei_SolicitingMaterial": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "SolicitingMaterial",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Soliciting Material",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
}
}
},
"auth_ref": [
"r8"
]
},
"dei_TradingSymbol": {
"xbrltype": "tradingSymbolItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "TradingSymbol",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Symbol",
"documentation": "Trading symbol of an instrument as listed on an exchange."
}
}
},
"auth_ref": []
},
"dei_WrittenCommunications": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "WrittenCommunications",
"presentation": [
"http://bioxceltherapeutics.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"label": "Written Communications",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
}
}
},
"auth_ref": [
"r18"
]
}
}
}
},
"std_ref": {
"r0": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12"
},
"r1": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b"
},
"r2": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b-2"
},
"r3": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b-23"
},
"r4": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "d1-1"
},
"r5": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "g"
},
"r6": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12, 13, 15d"
},
"r7": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "13e",
"Subsection": "4c"
},
"r8": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14a",
"Subsection": "12"
},
"r9": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14d",
"Subsection": "2b"
},
"r10": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "15",
"Subsection": "d"
},
"r11": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 10-K",
"Number": "249",
"Section": "310"
},
"r12": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 10-Q",
"Number": "240",
"Section": "308",
"Subsection": "a"
},
"r13": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 20-F",
"Number": "249",
"Section": "220",
"Subsection": "f"
},
"r14": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Form 40-F",
"Number": "249",
"Section": "240",
"Subsection": "f"
},
"r15": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240",
"Section": "13",
"Subsection": "a-1"
},
"r16": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Regulation S-T",
"Number": "232",
"Section": "405"
},
"r17": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "405"
},
"r18": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "425"
},
"r19": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "7A",
"Section": "B",
"Subsection": "2"
}
}
}
ZIP
13
0001104659-26-102570-xbrl.zip
IDEA: XBRL DOCUMENT
begin 644 0001104659-26-102570-xbrl.zip
M4$L#!!0 ( U0'%V@=B'/-0, ,, 1 8G1A:2TR,#(V,#@R-RYX
M
],_T'U:\8VAI( @622M,DP0TH*N34O'5D6H$9(CB0'IU]?
MR1=N!@*T]9.\.N?LKG97=O,T'E/PBH4DG+4LSRE9 #/$ \*&+>NN;Y_U+]IM
M"YR>?/P ]-/\9-O@DF :-, 7CNPV&_!C\ V.<0-<888%5%P<@WM((V/AEX1B
M 2[X.*188;V1>FJ 0Z>*@&UO(7N/6<#%7:\]E1TI%
S9CGY-))J2#^!9=7(4]\CC$+-:U(&5)_0 ^S=7?C?X
M_=0[Z/]XCM7XW/41?>F\35CW:_V7U_\>!MW:0ZW'+U.738E&> R!K@63+
2YC]>=?H*S4F CIH0]KX)[]7K=379S: $9^X+FTA77;/M0
MXJFRWB4;\(1)!1E:P =J2I@'5]UT
PDF,G"%_=?6&QI>K
M.3"2]A#"< H>0.DGHMG& E@*501JXS+(5F\AEBNAZ=8"X?SVK#W%^H3'"%,U
MTO,0XD@1E+2G(1R6:N4C/6,4CS%3EUR,O^ !C*B.Z26"E P(#BR@H!AB9?I-
MAA#A[87S_H6,<=WF>M0RB[&%(=%]/#5HDZE[0W"*;W5"P"STG+WKS>#<"ZYO
M#0N0H&6ERSG=7#G \)($D4V8AZPS4!%)GF]3)A-=QE<5(HD#KKL)%F' DM-
M3[+K:$/&SR";N0A2%-&]J+/X-C$S>WZFA
],UFWX@.APE4ALHYLW.>;8QV5[9KGA.+(-9I+L$,3N!W8+(>7L$L>:R
M7^5?KH.;A6FAZK9.UWPT-CI=R7'UE2ESR]XAS']B_B*&1&:G(!;*&2CA&@DC
M^MDN>;J(Z\-YCYF\R[V: /&(*?&V2R/,4_*7_:HQ^SG8KA Y/BV"^5_8U^T>
M75!TOJH%FFZJII=_ %!+ P04 " -4!Q=5K5"KOT* !_A@ %0 &)T
M86DM,C R-C X,C=?;&%B+GAM;,V=76_CN!6&[POT/[#N30N,XXF#72#9R2XR
MGF1A;#9)8\]LVT6QH"7&$2*3 24G]K\O*8FR1/)(2HJ2G(L9C_@>ZJ7XF*2^
MCC_]M-NDZ(7P+&'T?'1\]'&$"(U8G-#U^>CK8GRQF,WG(Y3EF,8X992
$X?V _H!F_(&?J94,)QSO@/Z!M.MW(+
MNTI2PM&,;9Y3DA-14.[X#'U_]%V$QN,!U7XC-&;\Z_V\KO8QSY^SL\GD]?7U
MB+(7_,KX4W84L
3_[YZ_4B>B0;/$ZH/&P1&:DH68LM[OCT]'12E"JI
MH=RM>*KV<3)1=NJ:16G2H6\XR9*SK+!WS2*<%[W>NQL$*N3_QDHVEIO&Q]/Q
MR?'1+HM'ZN 71Y"SE-R3!U0T\RS?/PN2LD2",*JV/7+R8#>3
:;D
5B B.Q,BFKZ!B!BST4$T-5=UT[BUKUIG(T9]QLNYP9
MBSHS$AVMV
_J=_#"6'XIFB__\,6-B(7"QRG*.HUS55#3C?&0IG^B6
MI/*"*U^81SV-JQ23B(FIZ3D?I^5A+,,?.-M8=UNUFED*_TA7=7QY6,0N *,M
M&2<9V_*(O*E7FFZAHU0YVJ1"(5=4A(Z_+D8_%AKTNU+]Y]/D4(N#CA9+H.V&
MT'PI:K2TH%WLJIMMIE0O-\N"Z&2+(;V/E01)C>,.OA [CN7.KU*\MMC7REUU
ML=66ZN-681"=;'.D]W*M05+DJYN_D"SBR;-
UHR5SWND6DT;?-S1A(6 :
M@TEH:#T-[/=DG
EJ0F*$8LQ$(U2BTJQ)R+^L15G[(2G^UXH
M#*5K+@"K.AJ:+"@Z[-Y 0&JY7T:6'-,LD0-8+R2FU/GI!F#6./70=$%Q IB#
M3TEJO5]2%H\D3>7M $S[!Q2;V#4ML&&=%U,9%#&@/9"9(@)5(>%@<_DB5^=B
MF32PL0V]3W@,VUW\U.)@$=(=#J2H"$,RSA-)C=L0/0P92M?T %9U;C194,38
MO8&LE')4Z/U#
%2B .%H.^M#0ZA]@G&59!%.2R]78EO6
MT3R+UC4@H%T=$D,8%"B0.Q"6,D Q4X1X!>9?!/-AN#24?F QK-I1J64!@J)[
MZ\-$ZKU ,MMRWG(-SSBPU-E-V1ZS]?U90!<$*#WFC+NVI;P%BJ<9Z)+F2;Z7
MC]/=;#
767@.;R(4:P.;K,
M+0%VDVT*VIJ 2+ : V@X:(MG2KT0,1,C$\?IG,9D]PO9@^TR=&Z9 &RVH=!$
M 5%A=P9@48E1H49"[@6,.YYL,-\ODJAGJC"%;M& C+;9T%4!P0%8 ^BHU&@Q
MG_F<299X-X\%J,E#4CX/WD,)J'<+2X_M-C. ."!TNAT"!(D@U([R"=*<1HP_
ML\;C#C.V%0/@?L9B>(72$^46JD%-:*/5&1(08$-\ IBU0C^4SZ0@)E_C*2I
ML@8OQ%W$L3A06?7/=4+),=A^J]8M71UVVTQ9A &1!+L#^*F4']0')&/0+0T%
MFND;FCKU#\UT*#33H*&9O@>:Y2L+!)J3-S3UQ#\T)T.A.0D:FI-W02,ZWNM8
M,Q,?;_F2O=H>S@:57I QK5J!.
+#)#K&1GB$Y-B877+[SA[26@$
M+YDAN1=@ --6:C1M>.C8#?;Q4R^(59S7L:9
)"T
MC?4.+J7:)Q)W+,MQ^N_DN?-$W"[V@H?5L!62EC(\5&SV^H I8Y (\G%B7>$J
M;VA87R73RMV] FRQ=7@%N%$8! 0V1^8KP.75DU+DNILEHYQ@8$1H%SOK9(NI
MNH\;96%TL6G(Z.'B>RTT/K[(,KM+>O?(*/R @"EQU=.0.=7;>GD0/0Z8TGN]
MD*%"Y^EJO,PPD=F'[T:9LYE=MU-/Y*H@B-[5W1C3M"IWW)N_\207>YZQS69+
MJ[L\MN<& 9VK7NZTJ7K<*@JB][N
;J&4DK#X(-P)3.0E&&V ,Z
MGOYM]7>DHAQW_PU;
Q35I4K"#HL*@XLDB!0@'WI--PP5$E1
MJ?61G:IEUM(
5O];6G(?]R%ST*4P1X(<$N
GZ^*?9_)3Y86@GHG.6T[+)9)[6TB8)@I,N9D=:R3#K7$".I=LW%-DYR$I=F
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MEB0@%FR^ !8**5):+RQ<;@A?B^GM9\Y>\\
I,
M%6'MD^LB$,E(G]F,FLGMX25>2^1X96PQJ"V,&XH@& %M0
SH_RPY9 $G\>7]/'@B7[QTLR2[_+';TU'&&,2#6]=G;X.;H)W.]@4%
M^%:WT*E>AIH5H)5\1JRJ OTN*T%%+;;?+V]NNA:?Q&:U2?RUPAD16_X+4$L#
M!!0 ( U0'%V/IB/O9 < .I7 5 8G1A:2TR,#(V,#@R-U]P
&ULS9S?<]HX$,??;^;^!Q_W# 1R:1N:W$U"0X=IVN1"VM[=2T?8 C21)4:2
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M*T\3>2W
\^%N:*:"I.KOK4']GRA2V-;%DTVWKAJ7G2N=67,N'+K)M2)FJZ]
M9:D]K?U86*Y]VGC%9;SG"'=QD6J?RJ:-Y_0UC5M3^=Q.*+-1Z)ZY#P[968[+
M_O,C/]'56!M%8K.IB9,QY7G]/ZS-@4F[!J\V)!YMC>5.[5L<^K0;ORL51U(E
M5%G6F[J(BO>B=MQ
!*B(SP!SJ7J@+\OB60]Q^8O,NT(6'^
M.R/*4,57$-)'QD#89YBP/0J1>#\J(C1S?"# CZV!Q-^@WGAX-"(A'\THYRZO
M(P+4RLOL@=C?8F+WZWP%X&^>W?ANAQ8X^YTB0/SO7@O^([5($;BGBLG$#ND*
MP/[(&$C]').Z1R$J[QN10&EO3<'Y#S[L WE(J =,QX07'@WL,1W&76(.18Z2
M
M1?A0)'3YB:Y"H(],H:11
_[EE@G9"H2@U!\\1X04@(/.58.^^#'L7CATE#ZV4^4JP
MG[X,^RD<.THN6BD3$WO??KQ3CW+AF8'V&D.1H^2B%1(Q@>
VCA6TIT8 +EBY*KELJI&ZF+L*+$WWSW+:! 41+0,C$U\[R5
M;NYC)D7P>>RQ%90K2B;I$U5WQ^O6%&OOI;_S-7@%&TJW>BBC9HS?%3/6@[Y,
MTTRLG]%X9L4\IE"\*.E?4%[-J$>2LY@9)J:?[1VB8H27
JM,=/[H=,YY>YL@*RAHEY?.)JIGM%_FHB-O -UJE8\G]VT-*
M#:&$41*\@+2:(>_Y48[WP 0*%B6S*Y6#U"?<+.,9$5/J7[U0;@D%C)+IA<2A
M];U34-\[?6'?BY+Q^40AL2W6AMLKZF[,V93X=Y(%"X#WV6 2#TBM>_]>ON7'
M[>U6:>['P'XHQ^XQA0+'V2(9DE
>3AK+XM%S=NQIWB)1XBXKP04/.(D8E@LTOHT0YW/[)E^
M((:L/0SQ]Y6 \D><4 R+15L_K_IVX)G*\)SY@2&4-N)2V%)I*)!'*>'\.M-,
M4!WL6PX,H9 1U[R62D.!?)-2-;6=VD
NQ'';B%%,9*+A"@/]9 ]E#OJQDJ_T)K)W[DW
M=^W>/^7.#&W>%EKT4%T*&@64=!4J&F=LW=G)'QQ:]^R@O!$3TS)A.'NFLC%G
M\8!+$KPOWS.#\D7,0DMDH>"])N))97,3K^Z5C"EUTR=Z>[4!$B)@!="0(.:G
M+T*!\[A IJG;3"3CI]',BM9WF
^Z%D2\N!-RQX(T&9+@0*]I?>7'L56$H-C
MIY8=DO[UW\Q(LN7$"=!+N=P]O6>W@*W':#3O&
!&PD8NE'X9M_U:NU
M?S$1NI'GA[TW_]J_;+7;__K/GO.ZGT S:!K*-TO])!GNK*[>W=U5[YK5*.ZM
MUK>WMU?'V&9)-=H9E[9KU&KUU>L/)Y=N7PQXQ0]EPD-79)T"/[R=/SZ^S9IV
MXL O-,4G9I+FZLS0\-;+.]B--U;5RT+3I+3INFJ:F*:^C-8:]
, 3V$(<:;U2:U0:&]8@%2G
X=9ZO2K)MQ9C:GN%)\W>$RP[@GIM!MYH07T*.Q;AJFLM+C?)@U[G+9
MH6'UB^G&<10(6=J:WA2:NU$:)O&D'!#]LM!!QLGLT/"PT.C@:K^=M>KXT=@5
M0=(7,1^*-/%=676C 7;8J&TU-I>0>P3W]AR&_[U._"00>Z]7U4_G]4 DG.%8
M%?$M]4=OEEI1F(@PJ5Q-AH!,5_WU9BD1XV256&P5>JVJ(5__7Z7"CGT1>#OL
M4B2[[)0/Q X;>^-=UCZD7[[6&D=?/UW^HW'X=G__''[@2EBE\L#.S<977.[7
M.
U^[/)#B$2,=6R,=
MA; ?DQ8,%?.@'7IB_%Y,OM9 7FTV:EO;S8,43C
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MLII*1FFL9X)&M.T[>O&TT*G%:U%E6@I:L'F8/?8]?-'U1
/>3,%DCV[>:;1
M5T!I&OH*G\!
Q*Q\R2*\[>/7OLT>"5C6C,>BC :^.$]<]Z+C^E)2X8UK^WE
M3Z-1LU[.:8KEM
3U\K&3=90,>]_QPAV'3VBY#LJOPP._!(Q>X
M1<1+>Z\[>__\6WVCMOMZM0.VQ7#OY\VD!K?TST4:B,HY[Y'JM96 &JV21,,=
M'$W_V8F2)!K0DSO?2_H(6>T?2X6>G2@&M*F>!P%W;UD#())1X'N[3+\TXZCW
M]?P]+K
^@#^'I4H88W ']KP7]:@'\/W6#MIYJID^G[:NC0W9YM7]U=/D<
M$UX>M3Y=M*_:1Y=L__20'5VWWNV?OCUBK;,/']J7E^VSTY]/EYV]SUSVP6U-
M(NA_6&U56:.VOK9=-O-#2.AAD,V"DA&ZHOMA,DOY-E7^*$I^SL1/1A''9Q
4_5ZI'$9NBA8;NCE?W
.W#F#]H
MNFW;IIL]Y]+>5N7]M*GV>A6AW
*_4@ZCK@_#X'3 !'&ON)#R,=C=T^
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M?=_7B6
P$*ERP=^,-FY#P^V?TC(_S'=@#D5##(E8AA'(Z3_
M&>70F.7IA>M=VCL4 ;\#-;-01R3>O9NCB"O;G\8_
W"?3WV P'
M=T1
7"'#1#GG!;ZG?&C=/KQM_^@Z5Q-_GK 6\ND:EWMS:V%Q?NV^_X)_X
M4=)N/L:?"#_+)!$(%G ^(DRVL1OP!:3GDVL"&O9U)UY5T/JV*'GU8\3X> K\
M^3AH18.!+[$>@0!"5F1J<_^'%MFN7E0OJP3,T6 81!,1T\ZR(E&STZ@ZL^J,
M;E?)4MC[J_B!"V73ON?%0DK]X\0/17V.6]<=>*
^OKZ\Y)%/;89[!=N^PP]D
S^!PL+A!_
O_;%^^\>W4A?SQNB"4[
X,5/]&SU&"A6SF, =7^D =,C(4+
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M==<=H@[,SK5[0B^L(& *X\0.#R?F73<* +LAV$3'\U\N?-S]B"/H]EQL^FX
MVA_;I_O+&I+XP:Y&MG^.Y:#HT6K5QKH?%ML'HIO,&H4M+7H_QWX"^XCN5!IJ
M?T*6R]_KPX.[MVN_#0_ )"QU<3X#MA"#\LG"9SN=* H$#ZE4;TJ2%V+AI
8HYN4X[ 4R7I@JW3H_O_< A1L:&4/L8Y$D=]:8UW1/1&\E
AL4PL>S:W@*'LA'?10;##0(
C,4@O3S
MU_(43 &C5UQK^*?7$/4UK])8[NC*D@?QB>KPBU.>05U,45=;RE3$]_++:#_>
M_^!_^OWZ_$7PR]H"?IE9T5^$:YJBLK;L/H)K=(?GX9KGK!
V* K9V?YP"_B"*&^_)"T\F@^TI03/JUN3#]^D0YHBL\(&AV3/T4
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MZ"[IH]$]Q,@\E\P373]49;I6'+.V;J+V4T%,=1*AR9:QX>8NQ3)KZPXUAKF
M4H98Y8OY&,M\;W0JC9(!R\XX9".C%9_WL\:N_I3$TDO
W7D1.H:3LH70Q][K"OZCND537
M[CKSA0^FNY4D8T5)YL^D$OL@IT0 /BW(J3 B#S>5@EK! G3"$B^Q\2D7J0[M
M(WG07,$$"?_.AZE1YH4 /KR)Q
EC%=^CHL3[O5A0;+F:
M1VN>.JBK%P]:26#_6G7=#W].R=34%.@<^F%V 1N3(D'E!?I*U^R$S.Q ,[.T
M6VD
JB8QQP3 /T%OH& @4#59K<$/;$AO0AQ+X)1G <$MTK9
M(F,"C*;5ZKNX$
XPL?[%?O^L,JF(FTYW;XX
M%5*^G6
?*9G]=U7*TP?7&6S!U<+O5O&'5']
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M$8WSCA^ 2XJKRU:JEDDUF8I48!SP4X#N<,
&.
M QTZ+KR4
3KF[NP6)!CV*$%LLQ/
V5*
2Q/R#:(DE(R^$Y9Y4.Z,P?$#
-3ZU[>JC6P-*R#Q9!I0560WC@8T*>!>WY*-W3A#>]M2&C;AY07Q0"%I
M0F$DI*I<[5B[/DMKY"S98^1*M
T)DS#TL>X@J8"17U*^MP()*_O.2]RADV
M.RL3=6Z4_C$R3!DCOG0 8P,^]@?^=Z&3KV@WD?&8\%O1!PL0-L\(F %H*A!F
M8-'Y8F0QJA(Z 2E6#C8'#(&V)^P?4CW:.O"0@VR&<;5,Z?N]/EY@U,&[76,'
M>JC?9)7MY^1M^W6\ S210V^=]T%C \^[P=!*77CZ/B%L!&(EX\N(;NUFA2@@
MX= 3KCX/OJ.H!MLM[>&UK')G=94,P"K8D0)<([JD6AMD.CH(O,_N!!C;P"P%
MLPZD_:7J!
A"CSG
MMAV&RWI@CO>*-@H8%VBC RXO^0 ,Y4L@;3% O46M^FC470#QQJF;@!T,VW5&
M1RKCHE=V<999&9D%JR; H(XDC42@0,^$ V?F1S0'EA$0VS.M. %5'Z)MJ:0<
MN,>%YE8
(&*[(H%! J@@/ E>N@#GL1M$C&0%T]WP49'"&W.73=
M0)((D5GP$8^UPW.'VMQ@L1#\?X 4U\H.&@L423#M"JCL'K &_1JA.A'PBQLI
M4RP1#CD=>)VS-CHF)(ZF<)=?#9&5X5/:@Q-5% 2*D3)/1?A/'Z9^J @#]S@@
MB_E=A)[//@IA=I[&+K@Z(D?[BTYS/#2DHKC8>+]4A4*I>23@T"']@[2HELXS
MBK.9=AI=Y_L9#Z/ECO;7(-($HB<"T(%.V7F?@Y1VR3?G@03G'*8/N59D;P>=
M=Z@"+N]\8)T %"XR!MCDVGTU)07&6<$ABV9LR20PAY=B= ,P>:*&Q#G,6(4
M9FY#!6"4(LNV9
R>H49A#Z9<_LL5'8^);MFUU/0'0Y&$(BTE%,K@L#:ON)+
M[GY+_1BD%-A*:)^9*= ID5HXA\H4DA3
F7##)2=[)A).R !MA0J>?39&U IHX#N$8
MVB^ML0IS7.7B/&-;E<<&_\_3"E!Y+^"?P*:"8==WM$V<^S9_7]^L6D[-/?,/
M@U0:=VC#ZHB-54@*;;D\/ J8B88D>#YD7'7.)V2O&LPDOB(1BC>D"7"T"H@E
MP.6HR+3O))1_)$\/]VF=[;?[)Q_:P!6;:[N,)Y4^]L-
NCP49I1(
MH2&?PL18G)+IBJ(6_0*0>13IH,\0! I\C95&+<,)X)H.5,14,Y C8*@1L,(\
M&Z 0)#9J
"!"HI
)H+QS7VH5.FA,2L],?+6K.$L^:U,HES%Z6!5Q0R&"<8I ,*AG<#
M<&96$+8J*QBV3F[8%D+H>4A\*E.11
$\9*R+-;<:,[F9!S,
MR:P\0GJMS.Q.MA^X ?H>"U=X:2Q(ZI>1 YLE!T=M7Y;>,S+7J 5XC0,G:C$R
M:S>'"&AK#29UUD[E=_J"QR98.+42O0 G7T#1A\!(F$KH_,_D
M KG"T#'&GH: $.BKG(05YX['Z%6@L:ALVI$(.8;9#5WH1 7N%+<]
LD7EAK@.A:YH
M/Y!H/PL=Z*)*$W/G)I113) JQOQ.%Q4A^1%UF546A*6RNF**_V$T#U0[I=-5
M"!%&Q4#M3,1[C@S*T)%%/[CKIC%W*8>9CYO)Q*F=?*'&PQ^E5_2V?"5YG#PK
M;0>#J @8,WIHM4H*).-&^!1*(I2M&*,KBR &Y"O'^%S),GI *1FRZ1'S*D(+
MN,\]*[K.'W@FG[S+_0!SW2C$N;I"*&^.<>G<-P>@LZWMD+ULP(IL4*T1T2]*
M!P-=$E#@"NAYYB81<(+3K)GPBJ&@(OA&]"KR1G<+P*I0@#);$N,>A>V,YOF?
M$(A9^)@1%O-$VRSE.;X)OI,H4MX
/
MS\V=2 6 A@2*2MI0*+
*'*NY)'2O,\2RK@V39I6A^Q
MN?H(](ESCQVGJGLZ0H0PO4<)I
M=,[-4E$4/335"
(<(*JQH7O",X?>&!??HHR82
MB_I\^A85-I>DJA*L ,*R')A#5IU"88F=&L-<=9P%[PVZU #Y_6H%6J ML
1.AJB.)0BSF0[5-M
M%4P43%!58$$(6C^R3SX&SA4CE67:YIYESU\QIS1P(E19!(#6U1MM(?Z%"H2'
MQ!2:OV(*+SNFH*]9WFN!S8QY%-"PI^#: 5,87@>F $KV*B=11+1[F9/KZU7_
M*2\G?1:%!6N]6LS]2@HI,Q:U%:T^T*NWF!6C IJQ!X*'5M3X//9'*&FLDZ0G
M\$/?1'F!E#?(CY1NKU?9YPC/
Z)05C[#)?4\&9)J#WS NL
M8@%5BZ5! 'FL"@LE5=G9%WWJ+_*25I^S&U7G>/Y.^;JF0V?;C2=IM8#M!AL[
MI#H%R^W$;E2=;=7$6$Y(YL?E);).9GY.F_NF9/R'RFG!S@R$55>$&-)!?.4S
M*'#S%3E4)(#-4%G!XD%_44(3]0L5(<@" K!EATMCZ)"5HSE$T92EV(CXNJ2M
M\OH'%>>)"V:4=EL<-%I4US34S[05QM%>1Y7J
:!HF@ W,\W19I+(2;1#58VJLW&[M,65
M>7A6]LK:]UU5_I>QFF/<- $+<_,8C=I7C?II^@K\;ZGO(=4@Y 8]T#.O.:%Y
M_%?WD">+.K0C"8C-8)*'W3+GFOQ+!9$IR%;!4#O)@7.-7IF:-VRC<3$36BD+
M1)IXI@-\0A=HF"DL
IHYA!Z=\75SZB_0#4)U/]+5(=\\C$PU,[X>TQ]0S-;1
M6U":FBX6-V53Y&7$9&JJ1
H@5(:CVJ;@/\Q
M) =NG4?E&>B$A/3(;)"TI!(5Y66.BJ+@7AK@9ZPG61#=5V
?@&V7[ "OD\38=Y('QJYQK\IA>
M&A!-VPPSO26&[[*9%NWZ='+'L5/6!2STP-F-44@"
T\5A9G,-K@$$S:UK^-,
MK'(I(]
GRMEQ;DP. ^2PUD 7%HV$
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MS3A60CNG9V/Z8.1
-"&1FS
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MS
5A5=>:/[,\
MQ)3L+;L);\51'0O78'DI2"B*YGB%H)O*R6 )DB#?#/5?1_1YT#7!!Y)9N@'*
MM!1/%=!PIIY#>#\I%?+S;X1^[+7/3WC)&5YXL9/5NVVI2H/2BTG="-
G=TL7]^].FJW;I<43O0/FU5%WS]]K'79&N4K]<6?\%8
M;VL%^0/@7*O6UH?3C%+)'IM!%X^I6ZU--?N!Q93-LFCF*7W2*>J3I;U5N
83SE""B3]$>C\9(72;\\_&B3IQ>9Q=
M-:A/6_ZE/NW[$'ML?9>=T3D3N<-.\&M[+\0\>YYDL37+I0"P\<+D'3;VQKNL
M?4B_?*UM'7RE*RM5)@[!H&[BO^/CF]]J[^]N]C_VCU8_GDW&ZR?#Z.V%:-Q<
M?$F^7'SYUHZWWJ9'@\GWWR_.5V_2C\G-9=.7\;[\L/WO#T
?_QXEHZ\L_?CR]OW9_UPO_E;Z^SC[17G=XVUF^A;P[O]OO%[:V.MD7[T
MY'OO]BYYNWK)KYO-UO7-ZG\_C
MMMK\/#T[;%V'[.MPXO(T&K1.O6>^M
MWGR+6KW)D7OM7;3^&Z;Q]4%RW=](CK
7PTQN%
MD=5.Y$WP9S\9!'O_#U!+ 0(4 Q0 ( U0'%V@=B'/-0, ,, 1
M " 0 !B=&%I+3(P,C8P.#(W+GAS9%!+ 0(4 Q0 ( U0
M'%U6M4*N_0H '^& 5 " 60# !B=&%I+3(P,C8P.#(W
M7VQA8BYX;6Q02P$"% ,4 " -4!Q=CZ8C[V0' #J5P %0
M @ &4#@ 8G1A:2TR,#(V,#@R-U]P
&UL4$L! A0#% @ #5 <
M73B2B1-,(@ J9P !( ( !*Q8 '1M,C8R-#(S,V0Q7SAK
:+FAT;5!+!08 ! $ 4! "G. !
end
XML
14
tm2624233d1_8k_htm.xml
IDEA: XBRL DOCUMENT
0001720893
2026-08-27
2026-08-27
false
0001720893
8-K
2026-08-27
BioXcel Therapeutics, Inc.
DE
001-38410
82-1386754
555 Long Wharf Drive
New Haven
CT
06511
475
238-6837
false
false
false
false
Common Stock, par value $0.001
BTAI
NASDAQ
false